Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cFK-9-USPIO is a targeted magnetic resonance (MR) molecular imaging nanoprobe designed to detect integrin αvβ6, a protein overexpressed in various tumors, including breast cancer. The agent consists of a novel RXDLXXL-coupled cyclic arginine-glycine-aspartate (RGD) nonapeptide (cFK-9) conjugated to N-amino-modified ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles. By binding specifically to integrin αvβ6, the nanoprobe facilitates the visualization of tumor progression and tumorigenesis via T2-weighted MRI. Preclinical studies in 4T1 mouse breast cancer models have demonstrated significant T2 signal reduction in tumors, indicating specific accumulation and potential for early cancer detection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cFK-9-USPIO.